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Sophocarpine is the major pharmacologically active compound of the traditional
Chinese herbal medicine Radix Sophorae Subprostratae which has been used in
treating hepatitis for years in China. It has been demonstrated that Sophocarpine
exerts an activity in immune modulation and significantly decreases the production
of inflammatory cytokines. However, the protective effects of Sophocarpine in T
cell-dependent immune hepatitis remained unknown. The aim of this study was to
determine the protective effects and pharmacological mechanisms of Sophocarpine on
Concanavalin A (ConA)-induced hepatitis, an experimental model of T cell-mediated
liver injury. BALB/C mice were pretreated with Sophocarpine or Bicyclol for five
consecutive days. Thirty minutes after the final administration, the mice were injected
with 15 mg·kg−1 of ConA intravenously. The results indicated that pretreatment with
Sophocarpine significantly ameliorated liver inflammation and injury as evidenced by
both biochemical and histopathological observations. Moreover, in Sophocarpine-
pretreated mice, liver messenger RNA expression levels of chemokines and adhesion
molecules, such as macrophage inflammatory protein-1α, CXC chemokine ligand
10, and Intercellular adhesion molecule-1, were markedly reduced. Further studies
revealed that Sophocarpine significantly downregulated the expression of T-bet via
inhibition of signal transducers and activators of transcription1 (STAT1) activation and
overexpression of suppressor of cytokine signaling1, inhibiting the activation of Th1
cells and the expression of Interferon-γ (IFN-γ). Altogether, these results suggest new
opportunities to use Sophocarpine in the treatment of T cell-mediated liver disease. In
summary, Sophocarpine could attenuate ConA-induced liver injury, and the protective
effect of Sophocarpine was associated with its inhibition effect of pro-inflammatory
cytokines, chemokines, and the IFN-γ/STAT1 signaling pathway.
Keywords: Sophocarpine, Concanavalin A-induced hepatitis, interferon-γ, signal transducers and activators of
transcription1, suppressor of cytokine signaling1
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ConA, Concanavalin A; CXCL10,
chemokine ligand 10; ICAM-1, intercellular adhesion molecule-1; IFN-γ, interferon-γ; IL, interleukin; LPS,
lipopolysaccharide; MIP-1α, macrophage inflammatory protein-1α; SOCS1, suppressor of cytokine signaling 1; STAT1,
signal transducers and activators of transcription1; TBIL, total bilirubin; TGF-β1, transforming growth factor-β1; TNF-α,
tumor necrosis factor-α
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INTRODUCTION
Hepatitis, which is caused by alcohol drinking, certain drugs,
viral infection, or autoimmunity, is a serious threat to human
health (Zheng et al., 2016). ConA-induced autoimmune hepatitis
has been widely used in studies of immune hepatitis treatment
in humans which has been considered a well-established
experimental model for immune-mediated liver injury. CD4 T
cells were essential to mediate adaptive immunity in response
to a variety of pathogens. Intravenous application of the ConA
in mice results in the activation of naive CD4 T cells and then
subsequent differentiation into T helper cells, including Th1
(secrete IFN-γ), Th2 [secrete Interleukin-4 (IL-4)], Th17 cells
(secrete IL-17), and Treg cells (Schumann et al., 2003; Siebler
et al., 2003; Stummvoll et al., 2008; Manns et al., 2015). In
the pathogenesis of ConA injection, IFN-γ was reported to be
critically involved in liver injury because in the mice deficient in
IFN-γ or treated with IFN-γ–neutralizing monoclonal antibody
its disease progress was significantly reduced (Miyagi et al.,
2004). IFN-γ was also reported to activate STAT1, inducing
T-bet expression, which is essential for Th1 cell differentiation
(Shinohara et al., 2005; Zhu et al., 2010). SOCS1 is a negative
regulator of STAT1 activation. It has been reported that
overexpression of SOCS1 prevents ConA-induced liver injury by
suppressing STAT1 activation (Ogata et al., 2006).
Sophocarpine exhibits many pharmacological activities and
is a major matrine-type alkaloid present in the traditional
Chinese herb, Radix Sophorae Subprostratae. Sophocarpine has
been demonstrated to alleviate pain effectively in thermally and
chemically induced mouse models (Gao et al., 2009), and it
also inhibits LPS-mediated NF-κB activation in RAW 264.7 cells
(Gao et al., 2012). Moreover, Sophocarpine can decrease serum
levels of aminotransferase and TBIL and alleviate liver fibrosis by
inhibiting the TLR4 pathway (Qian et al., 2014). It also exerts an
activity in immune modulation (Zhang et al., 2007). Despite the
evidence presented by these experimental studies, little is known
regarding the effect of Sophocarpine on ConA-induced immunity
hepatitis.
The aim of this study was to determine whether Sophocarpine
could inhibit immune-mediated liver disease in T cell-dependent
hepatitis mouse model. In addition, we aimed to define potential
mechanisms by which Sophocarpine exerts its hepatoprotective
role in ConA-induced liver injury.
MATERIALS AND METHODS
Mice
Male BALB/C mice, weighing approximately 18 ± 22 g, were
acquired from SPF Animals Biotechnology Co., Ltd. (Beijing,
China) (Certification number SCXK-JING 2011-0004). The mice
were housed in the Institutional Laboratory Animal Care center
at 302 Military Hospital. All of the animals were maintained
according to the National Institutes of Health Guidelines for
Animal Care and the Guidelines of Scripps. The protocol was
approved by the Committee on the Ethics of Animal Experiments
of the 302 Military Hospital (approval ID: IACUC-2016-008).
Efforts were made to minimize animal suffering and to reduce
the number of animals used in the experiments. The animals
were randomized into Control, Model, Bicyclol (100 mg·kg−1),
Sophocarpine (30 and 60 mg·kg−1) groups. The drugs were
dissolved in saline and orally administered for five consecutive
days. All of the mice in the control group were intragastrically
administered with an equivalent volume of free saline. Thirty
minutes after the final administration of medication, the mice
were injected with 15 mg·kg−1 of ConA intravenously by tail
except for the normal group. The mice were sacrificed 8 h
after injection. Blood samples were obtained, and the liver was
collected simultaneously.
Blood Chemistry Measurement
The serum levels of ALT, AST, and TBIL were determined using
the detection kits provided by Nanjing Jiancheng Bioengineering
Institute (Nanjing, China). All procedures were performed
according to the manufacturer’s instructions. Serum was diluted
fivefold for the detection of aminotransferase.
Liver Histology, TUNEL Staining, and
Immunohistochemistry
Livers were fixed with 4% paraformaldehyde and embedded in
paraffin. Next, they were cut into 5 µm-thick sections and the
sections were stained with hematoxylin and eosin (H&E) or a
TUNEL kit was used (Promega, USA). Immunohistochemistry
was performed by liver sections and stained with ICAM-1
antibody. The levels of tissue damage and immune complexes
were examined using light microscopy.
Analysis of Plasma Cytokines
Plasma concentrations of TNF-α, IFN-γ, IL-10, and TGF-β1 were
determined using ELISA kits (MultiSciences Biotech Co., Ltd.,
Hangzhou, China) according to the manufacturer’s instructions.
All indexes were measured 8 h after ConA injection.
Quantitative PCR
Total RNA was isolated from liver tissues by Trizol (Life
Sciences) and first-strand cDNA synthesis was performed in
20 µl of solution using the Revert kit (Thermo-Fisher). The
mRNA expression level was quantified using real-time PCR
(Applied Biosystems 7500 Real-Time PCR System) and a SYBR
Green PCR Mix kit (Life Sciences). The primers sequences were
as follows: GAPDH, 5′-GTCCTCAGTGTAGCCCAAGAT-3′
and 5′-CAATGTGTCCGTCGTGGATCT-3′; T-bet, 5′-TGCC
CGAACTACAGTCACGAAC-3′ and 5′-AGTGACCTCGCCTG
GTGAAATG-3′; GATA3, 5′-GGAGGACTTCCCCAAGAGCA-
3′ and 5′-CATGCTGGAAGGGTGGTGA-3′; SOCS1, 5′-TCCGA
TTACCGGCGCATCACG-3′ and 5′-CTCCAGCAGCTCGAAA
AGGCA-3′; MIP-1α, 5′-CACCCTCTGTCACCTGCTCAA-3′
and 5′-ATGGCGCTGAGAAGACTTGGT-3′; ICAM-1, 5′-CCAT
CACCGTGTATTCGTTTCC-3′ and 5′-CTGGCGGCTCAGTAT
CTCCTC-3′; CXCL10, 5′-TCCAGTTAAGGAGCCCTTTTAGA
CC-3′ and 5′-TGAAATCATCCCTGCGAGCCTAT-3′. The CT
values were then converted to fold induction over normal at time
zero (control) using the 2−11CT formula.
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Isolation of Lymphocytes and Flow
Cytometry
1∗106 splenocytes from the different groups of experimental
mice were stimulated for 6 h with PMA (100 ng/µl), Ionomycin
(1 µg/µl), and Monensin (1 µg/µl) and stained with the
Percy/cy5.5-conjugated anti-CD3 (Dakewe Biotech Co., Ltd.)
and PE/cy-7-conjugated anti-CD8 (Dakewe Biotech Co., Ltd.);
fluorescence antibodies specific for surface antigens were used
according to the manufacturer’s instructions. For intracellular
cytokine staining, the cells were fixed, permeabilized, and stained
with PE-conjugated anti-IL-4 (BD Biotech Co., Ltd.) and FITC-
conjugated anti-IFN-γ (BD Biotech Co., Ltd.). The stained cells
were analyzed using a flow cytometer (BD Canto II), and the data
were analyzed using FlowJo 7.6.1.
Western Blotting Analyses
Liver tissue was lysed on ice with RIPA buffer (G2002) containing
a protease inhibitor mixture. After centrifugation, the samples
were incubated for 10 min at 4◦C to separate any debris. The
membrane was incubated with antibodies against β-actin, T-bet,
STAT1, and phospho-STAT1 (Tyr705) in TBS/T containing
5% non-fat milk overnight at 4◦C. After incubation with
the appropriate peroxidase-conjugated secondary antibody, the
membrane was washed in TBST for 5 min.
Statistical Analysis
All results are expressed as the mean ± SD and analyzed using
SPSS software (version 20.0; SPSS, Inc., Chicago, IL, USA).
Differences were considered to be significant when p < 0.05 and
highly significant when p< 0.01.
RESULTS
Effects of Sophocarpine on Serum in
ConA-Induced Acute Hepatitis
To examine the effect of Sophocarpine on ConA-induced
acute hepatitis, mice were pretreated with Sophocarpine (30
or 60 mg·kg−1) for five consecutive days. Bicyclol, as a novel
derivative of Bifendate (Yuan et al., 2016) which has been
confirmed to decrease the levels of serum ALT served as
a positive parallel control, and control mice received saline
accordingly. Thirty minutes after the final dose of medication,
all the mice were injected with 15 mg·kg−1 of body weight
of ConA via the tail vein except the normal group. Eight
hours later, plasma was obtained and serum levels of ALT,
AST, and TBIL were measured. Compared with the normal
group, the ALT (Control: 8.20 ± 1.24, Model: 957.92 ± 76.46),
AST (Control: 5.64 ± 1.45, Model: 344.98 ± 58.50), and TBIL
(Control: 1.26 ± 0.66, Model: 9.99 ± 2.67) in the ConA
group were significantly increased. Administration of Bicyclol
and Sophocarpine inhibited the elevation of ALT [Bicyclol:
628.12 ± 205.94, Sophocarpine (30 mg·kg−1): 398.02 ± 178.35,
Sophocarpine (60 mg·kg−1): 171.25 ± 113.68], AST [Bicyclol:
219.81 ± 83.58, Sophocarpine (30 mg·kg−1): 157.69 ± 59.55,
Sophocarpine (60 mg·kg−1): 84.46 ± 25.28], and TBIL [Bicyclol:
5.08 ± 1.13, Sophocarpine (30 mg·kg−1): 5.05 ± 1.42,
Sophocarpine (60 mg·kg−1): 3.21 ± 1.25] compared with the
ConA group (Figures 1A–C). Moreover, Sophocarpine inhibited
ConA-induced aminotransferase release and TBIL increase in a
dose-dependent manner. Taken together, these data significantly
show the protective effect of Sophocarpine in ConA-induced
hepatitis.
Sophocarpine Attenuated Immunological
Liver Injury in Mice
Histopathological examinations of livers showed that, compared
with the normal group, the model group revealed severe
injury characterized by extensive inflammatory infiltration
around the central veins (Figures 2A,B). In contrast, mice
pretreated with Bicyclol and Sophocarpine demonstrated
much less inflammatory infiltration (Figures 2C–E). In the
Sophocarpine-pretreated group, only a few hepatocytes exhibited
TUNEL-positive nuclei compared with the model group
(Figures 2F–K) [Control: 0.57 ± 0.26, Model: 13.53 ± 3.86,
Bicyclol: 6.23 ± 1.22, Sophocarpine (30 mg·kg−1): 8.43 ± 1.91,
FIGURE 1 | Effects of Sophocarpine on serum in ConA-induced acute hepatitis. Female BALB/c mice were pretreated with Sophocaripine (30, 60 mg·kg−1)
and Bicyclol at 30 min before ConA injection. Serum transaminase ALT (A) and AST (B) TBIL (C) levels were determined 8 h after ConA injection. Data is expressed
as mean ± SD (n = 12; ∗p < 0.05, ∗∗p < 0.01 compared with the control group, #p < 0.05,##p < 0.01 compared with the model group, respectively). Saline group
(Con group), ConA group (Mod group), Bicyclol group (Bic group), 30 mg·kg–1of Sophocarpine group (Sop30 group), and 60 mg·kg–1 of Sophocarpine group
(Sop60 group).
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FIGURE 2 | Sophocarpine attenuated immunological liver injury in mice. Mice were treated with different doses of Sophocarpine. Representative photographs
of six animals show the effect of Sophocarpine, which was confirmed by hematoxylin and eosin (H&E) and TUNEL Staining. HE staining for (A) control mice, (B)
model mice, (C) Bicyclol group, (D) 30 mg·kg–1of Sophocarpine group, (E) 60 mg·kg–1of Sophocarpine group. TUNEL staining for (F) control mice, (G) model mice,
(H) Bicyclol group, (I) 30 mg·kg–1of Sophocarpine group, (J) 60 mg·kg–1of Sophocarpine group, and (K) Percentage of TUNEL-positive cells (∗∗p < 0.01 compared
with the control group, #p < 0.05, ##p < 0.01 compared with the model group, respectively) (H&E, magnification ×200; TUNEL, magnification ×200).
Sophocarpine (60 mg·kg−1): 4.33 ± 0.90], indicating markedly
reduced apoptosis in Sophocarpine-pretreated mice. Altogether,
these results showed that Sophocarpine dose-dependently
inhibited ConA-induced liver inflammation and cell death.
Sophocarpine Inhibited the Expression
of Chemokines and Adhesion Molecules
in Mice with ConA-Induced Hepatitis
In ConA-induced hepatitis, the expression of chemokines and
adhesion molecules were demonstrated to play important
roles in recruiting lymphocytes into the liver to aggravate
liver injury, such as MIP-1α, CXCL10, and ICAM-1 (Ajuebor
et al., 2004; Kawasuji et al., 2006; Sahin et al., 2013).
Thus, further studies were performed to examine the changes
induced by these factors in the mice liver. Liver tissues were
obtained 8 h after ConA administration, and mRNA expression
levels of MIP-1α, CXCL10, and ICAM-1 were measured. As
shown in Figure 3, the mRNA levels of MIP-1α [Control:
1.00 ± 0.72, Model: 41.47 ± 17.03, Sophocarpine (30 mg·kg−1):
16.80± 8.45, Sophocarpine (60 mg·kg−1): 3.32± 0.84], CXCL10
[Control: 1.00 ± 0.29, Model: 123.72 ± 22.81, Sophocarpine
(30 mg·kg−1): 57.05 ± 16.03, Sophocarpine (60 mg·kg−1):
18.56 ± 4.59], and ICAM-1[Control: 1.00 ± 0.19, Model:
43.44 ± 12.33, Sophocarpine (30 mg·kg−1): 20.69 ± 6.41,
Sophocarpine (60 mg·kg−1): 3.35 ± 0.50] were dramatically
reduced by pretreatment with Sophocarpine. Taken together,
these results indicate that pretreatment with Sophocarpine
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FIGURE 3 | Sophocarpine inhibited chemokine and adhesion molecule expression in the liver. BALB/C mice received Sophocarpine pretreatment and
ConA injection, 8 h later liver tissues were obtained for quantitatively PCR and immunohistochemistry for ICAM-1. The mRNA expression levels of MIP-1α (A),
CXCL10 (B), and ICAM-1 (C). The immunohistochemistry of ICAM-1 for control mice (D), model mice (E), 30 mg·kg–1of Sophocarpine group (F), 60 mg·kg–1of
Sophocarpine group (G) (n = 6 each group). ∗∗p < 0.01 compared with the control group, #p < 0.05, ##p < 0.01 compared with the model group.
significantly reduced ConA-induced intrahepatic inflammatory
cell infiltration.
Sophocarpine Inhibited the Production of
IFN-γ in Mice with ConA-Induced
Hepatitis
It was previously reported that following ConA administration,
immune cells were activated. Consequently, various cytokines
that aggravated the liver injury were released (Miyagi et al., 2004;
Wang et al., 2012). To examine the protective mechanisms of
Sophocarpine against liver injury, the effects of Sophocarpine
on the serum levels of IFN-γ, TNF-α, IL-10, and TGF-β1
were measured using ELISA. The percentage of CD4+IFN-γ+
and CD4+IL-4+ in Sophocarpine-pretreated mice splenocytes
were examined using flow cytometry. These results showed
that Sophocarpine inhibited the production of IFN-γ [Control:
59.52 ± 23.83, Model: 3248.00 ± 141.02, Sophocarpine
(30 mg·kg−1): 2831.00 ± 160.28, Sophocarpine (60 mg·kg−1):
2030.00 ± 242.52] and TNF-α [Control: 245.52 ± 73.64, Model:
998.35 ± 266.91, Sophocarpine (30 mg·kg−1): 1009.78 ± 279.96,
Sophocarpine (60 mg·kg−1): 540.99 ± 116.05] in serum
and decreased the percentage of CD4+ IFN-γ+ [Control:
1.47 ± 0.47, Model: 2.89 ± 0.10, Sophocarpine (30 mg·kg−1):
1.87 ± 0.45, Sophocarpine (60 mg·kg−1): 1.41 ± 0.77] in
splenocytes compared with the model group (Figure 4),
but there was no significant difference among the treatment
groups in regards to the percentage of CD4+IL-4+ and the
expression of IL-10 and TGF-β1. Therefore, Sophocarpine
effectively suppressed the production of IFN-γ and TNF-α
and reduced the liver damage caused by these inflammatory
cytokines.
Sophocarpine Downregulated the
Expression of T-bet via Inhibition of
STAT1 Activation and Overexpression
SOCS1
It has been previously shown that ConA-mediated liver
damage can be prevented by blocking antibodies against IFN-
γ rather than TNF, suggesting that IFN-γ is an essential key
regulator in ConA-induced liver injury (Tagawa et al., 1997).
The transcription factor STAT1, which is associated with the
IFN-γ signaling pathway, is crucial for ConA-induced hepatitis.
Activation of STAT1 by IFN-γ is significant for the induction of
T-bet during Th1 cells differentiation (Siebler et al., 2003; Jaruga
et al., 2004). Therefore, we investigated the effect of Sophocarpine
on the activation of STAT1 and the expression of T-bet in
ConA-induced hepatitis. In the present study, Sophocarpine
effectively inhibited STAT1 synthesis and activation as well as
the expression of T-bet (Figure 5). SOCS1 has been shown
to suppress inflammation and is indispensable for the negative
regulation of STAT1 (Hashimoto et al., 2009). Therefore,
gene expression analysis of the SOCS1 protein in the mouse
livers was performed. The results indicated that Sophocarpine
downregulated the expression of T-bet [Control: 27.44 ± 11.55,
Model: 67.74± 10.58, Sophocarpine (30 mg·kg−1): 36.81± 4.51,
Sophocarpine (60 mg·kg−1): 27.99 ± 5.03] via inhibition of
STAT1 activation [Control: 24.22± 14.78, Model: 205.49± 21.08,
Sophocarpine (30 mg·kg−1): 75.72 ± 16.64, Sophocarpine
(60 mg·kg−1): 8.21 ± 3.34] and overexpression of SOCS1
[Control: 1.00 ± 0.58, Model: 1.76 ± 0.31, Sophocarpine
(30 mg·kg−1): 2.21 ± 0.12, Sophocarpine (60 mg·kg−1):
3.83 ± 0.69], suggesting that Sophocarpine decreased the release
of IFN-γ by inhibiting the activation of the IFN-γ/STAT1
signaling pathway and Th1 differentiation.
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FIGURE 4 | Sophocarpine inhibited production of IFN-γ in ConA-induced hepatitis mice. Blood samples were collected at 8 h after ConA injection. Serum
levels of cytokines were detected by ELISA. Influences of Sophocaripine on inflammatory cells were measured by Flow Cytometric. Data is expressed as mean ± SD.
Serum ELISA for (A) IFN-γ, (B) TNF-α, (C) IL-10, (D) TGF-β1. Flow cytometry for (E) CD4+ IFN-γ+, and (F) CD4+ IL-4+. Representative photos of each group for (G)
CD4+ IFN-γ+, (H) CD4+ IL-4+. (n = 6; ∗p < 0.05, ∗∗p < 0.01 compared with the control group, #p < 0.05, ##p < 0.01 compared with the model group).
DISCUSSION
An increasing number of traditional Chinese herbal medicines
have been reported to serve as potential therapeutic protection
against liver disease (Ding et al., 2012; Hu et al., 2013).
Sophocarpine is a quinolizidine alkaloid extracted from Radix
Sophorae Subprostratae a traditional Chinese herb that has been
widely used in the treatment of liver diseases for years in
China. In previous studies, Sophocarpine has been reported to
significantly decrease the production of inflammatory cytokines
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FIGURE 5 | Sophocaripine downregulated the expression of T-bet via inhibiting STAT1 activation and overexpression of SOCS1. Mice received
Sophocaripine pretreatment and ConA injection as described. The mRNA expression levels of (A) SOCS1, (B) GATA3, (C) T-bet were measured by q-pcr (n = 6 each
group). The protein expression of (D) T-bet, pSTAT1, STAT1 were measured by Western blot. (E) The data analysis of Western blot (n = 3). ∗∗p < 0.01 compared
with the control group, #p < 0.05, ##p < 0.01 compared with the model group.
and attenuate liver injury induced by Poly I: C/D-GalN and
suppressed NK cell activation (Huang et al., 2016).
In the present study, we showed that Sophocarpine could
protect against T cell-dependent immune hepatitis induced
by ConA. Pretreatment with Sophocarpine significantly and
dose-dependently downregulated the levels of ALT, AST, and
TBIL. Histological staining significantly demonstrated that liver
inflammation and apoptotic necrosis was dramatically reduced
in Sophocarpine-pretreated mice. Sophocarpine also significantly
reduced the release of chemokines and adhesion molecules as well
as pro-inflammatory cytokines.
Con A is a well-known T-cell mitogen, after ConA
administration, the levels of inflammatory cytokine is elevate
subsequently resulting in abundant liver necrosis with mass
lymphocytes infiltration (Kato et al., 2013). Chemokines and
adhesion molecules play important roles in inflammatory and
immune responses in ConA-induced hepatitis (Luo et al., 2015).
Chemotactic factors was activated which attracted leukocytes
into the liver to amplify the inflammatory response (Xu et al.,
2008). MIP-1α has been shown to significantly contribute to the
pathogenesis of ConA-induced hepatitis as hepatic injury was
strikingly attenuated in mice with MIP-1α deficiency (Ajuebor
et al., 2004). In addition, CXCL10 has been reported to be a
specific chemoattractant for T lymphocytes, and the expression
of CXCL10 was specifically induced in the livers of mice
treated with ConA (Tamaru et al., 2000). Furthermore, ICAM-
1 has been reported to contribute to the development of
hepatitis by mediating adhesion and supporting the migration of
lymphocytes into the liver (Kawasuji et al., 2006). In the present
study, we found that Sophocarpine inhibited MIP-1α, CXCL10,
and ICAM-1 mRNA expression, which in turn inhibited the
infiltration of leukocytes, thereby alleviating the liver damage
induced by ConA.
IFN-γ has been reported to be a critical mediator of liver
injury in the pathogenesis of ConA-induced hepatitis (Kusters
et al., 1996). ConA-mediated liver damage may be prevented
by blocking IFN-γ (Tagawa et al., 1997). Furthermore, IFN-γ is
a major cytokine responsible for STAT1 activation. Disruption
of the IFN-γ or STAT1 genes abolished elevated ALT activities
and necrosis, suggesting that IFN-γ/STAT1 plays an essential
role in ConA-induced hepatitis (Hong et al., 2002). In this
signaling pathway, SOCS1 was considered as an important
negative regulation of the cytokine-JAK–STAT pathway and
forced expression of SOCS1 could prevented ConA-induced
liver injury by suppressing STAT1 activation (Torisu et al.,
2008; Yoshimura, 2009). Constitutive activation of STAT1 as
well as constitutive expression of IFN-γ-inducible genes was
observed in SOCS1 KO mice. Furthermore, T cell-specific SOCS1
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deficient mice demonstrated an enhanced sensitivity to ConA-
induced hepatitis (Hashimoto et al., 2011; Yoshimura et al., 2012).
In the current study, Sophocarpine pretreatment significantly
inhibited STAT1 activity and increased the expression of SOCS1,
subsequently downregulating its signaling proteins T-bet and
inhibiting the production of Th1 cytokines, which protects
mice from ConA-induced acute hepatitis. However, the precise
mechanism underlying this process remains unknown.
CONCLUSION
In summary, we used the T cell-dependent hepatitis mouse model
to examine the protective effects of Sophocarpine. In the present
study, Sophocarpine attenuated ConA-induced liver injury in
mice. The protective effect of Sophocarpine was associated with
its inhibition of inflammatory mediators, chemokines, and the
STAT1 signaling pathway. Taken together, the results of this study
provide new opportunities for the use of Sophocarpine in the
prevention and treatment of immune-mediated liver disease.
AUTHOR CONTRIBUTIONS
Z-FB, J-BW, and X-HX contributed to research design; X-XS
performed the research; S-JL, H-HS, and R-LW provided
innovative views and opinions; Y-MZ, Y-MG, and MN analyzed
the data; and X-XS and C-EZ wrote the manuscript.
ACKNOWLEDGMENTS
This work was supported by the National Natural Science
Foundation of China (no. 81330090) and the Chinese Medicine
Antiviral Collaborative Innovation Center (no. XTCX2014
B01-06).
REFERENCES
Ajuebor, M. N., Hogaboam, C. M., Le, T., Proudfoot, A. E., and Swain, M. G.
(2004). CCL3/MIP-1α is pro-inflammatory in murine T cell-mediated hepatitis
by recruiting CCR1-expressing CD4+ T cells to the liver. Eur. J. Immunol. 34,
2907–2918. doi: 10.1002/eji.200425071
Ding, R. B., Tian, K., Huang, L. L., He, C. W., Jiang, Y., Wang, Y. T., et al.
(2012). Herbal medicines for the prevention of alcoholic liver disease: a review.
J. Ethnopharmacol. 144, 457–465. doi: 10.1016/j.jep.2012.09.044
Gao, Y., Jiang, W., Dong, C., Li, C., Fu, X., Min, L., et al. (2012). Anti-inflammatory
effects of sophocarpine in LPS-induced RAW 264.7 cells via NF-κB and
MAPKs signaling pathways. Toxicol. In Vitro 26, 1–6. doi: 10.1016/j.tiv.2011.
09.019
Gao, Y., Li, G., Li, C., Zhu, X., Li, M., Fu, C., et al. (2009). Anti-nociceptive and
anti-inflammatory activity of sophocarpine. J. Ethnopharmacol. 125, 324–329.
doi: 10.1016/j.jep.2009.06.036
Hashimoto, M., Ayada, T., Kinjyo, I., Hiwatashi, K., Yoshida, H., Okada, Y., et al.
(2009). Silencing of SOCS1 in macrophages suppresses tumor development by
enhancing antitumor inflammation. Cancer Sci. 100, 730–736. doi: 10.1111/j.
1349-7006.2009.01098.x
Hashimoto, M., Hiwatashi, K., Ichiyama, K., Morita, R., Sekiya, T., Kimura, A.,
et al. (2011). SOCS1 regulates type I/type II NKT cell balance by
regulating IFNγ signaling. Int. Immunol. 23, 165–176. doi: 10.1093/intimm/
dxq469
Hong, F., Jaruga, B., Kim, W. H., Radaeva, S., El-Assal, O. N., Tian, Z., et al. (2002).
Opposing roles of STAT1 and STAT3 in T cell–mediated hepatitis: regulation by
SOCS. J. Clin. Invest. 110, 1503–1513. doi: 10.1172/JCI15841
Hu, Y., Wang, S., Wu, X., Zhang, J., Chen, R., Chen, M., et al. (2013). Chinese herbal
medicine-derived compounds for cancer therapy: a focus on hepatocellular
carcinoma. J. Ethnopharmacol. 149, 601–612. doi: 10.1016/j.jep.2013.
07.030
Huang, Y. Q., Li, P. Y., Wang, J. B., Zhou, H. Q., Yang, Z. R., Yang, R. C.,
et al. (2016). Inhibition of sophocarpine on poly I: C/D-GalN-induced
immunological liver injury in mice. Front. Pharmacol. 7:256. doi: 10.3389/fphar.
2016.00256
Jaruga, B., Hong, F., Kim, W.-H., and Gao, B. (2004). IFN-γ/STAT1 acts as a
proinflammatory signal in T cell-mediated hepatitis via induction of multiple
chemokines and adhesion molecules: a critical role of IRF-1. Am. J. Physiol.
Gastrointest. Liver Physiol. 287, G1044–G1052. doi: 10.1152/ajpgi.00184.
2004
Kato, J., Okamoto, T., Motoyama, H., Uchiyama, R., Kirchhofer, D., Van
Rooijen, N., et al. (2013). Interferon-gamma-mediated tissue factor expression
contributes to T-cell-mediated hepatitis through induction of hypercoagulation
in mice. Hepatology 57, 362–372. doi: 10.1002/hep.26027
Kawasuji, A., Hasegawa, M., Horikawa, M., Fujita, T., Matsushita, Y.,
Matsushita, T., et al. (2006). L-selectin and intercellular adhesion molecule-1
regulate the development of Concanavalin A-induced liver injury. J. Leukoc.
Biol. 79, 696–705. doi: 10.1189/jlb.0905527
Kusters, S., Gantner, F., Kunstle, G., and Tiegs, G. (1996). Interferon gamma plays
a critical role in T cell-dependent liver injury in mice initiated by concanavalin
A. Gastroenterology 111, 462–471. doi: 10.1053/gast.1996.v111.pm869
0213
Luo, Q., Zhu, L., Ding, J., Zhuang, X., Xu, L., and Chen, F. (2015). Protective effect
of galangin in Concanavalin A-induced hepatitis in mice. Drug Des. Devel. Ther.
9, 2983–2992. doi: 10.2147/DDDT.S80979
Manns, M. P., Lohse, A. W., and Vergani, D. (2015). Autoimmune hepatitis–update
2015. J. Hepatol. 62, S100–S111. doi: 10.1016/j.jhep.2015.03.005
Miyagi, T., Takehara, T., Tatsumi, T., Suzuki, T., Jinushi, M., Kanazawa, Y., et al.
(2004). Concanavalin a injection activates intrahepatic innate immune cells
to provoke an antitumor effect in murine liver. Hepatology 40, 1190–1196.
doi: 10.1002/hep.20447
Ogata, H., Chinen, T., Yoshida, T., Kinjyo, I., Takaesu, G., Shiraishi, H., et al.
(2006). Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-
mediated TGF-beta1 production. Oncogene 25, 2520–2530. doi: 10.1038/sj.onc.
1209281
Qian, H., Shi, J., Fan, T. T., Lv, J., Chen, S. W., Song, C. Y., et al. (2014).
Sophocarpine attenuates liver fibrosis by inhibiting the TLR4 signaling pathway
in rats. World J. Gastroenterol. 20, 1822–1832. doi: 10.3748/wjg.v20.i7.1822
Sahin, H., Borkham-Kamphorst, E., Berres, M. L., Kaldenbach, M., Schmitz, P.,
Weiskirchen, R., et al. (2013). Proapoptotic effects of the chemokine, CXCL 10
are mediated by the noncognate receptor TLR4 in hepatocytes. Hepatology 57,
797–805. doi: 10.1002/hep.26069
Schumann, J., Prockl, J., Kiemer, A. K., Vollmar, A. M., Bang, R., and Tiegs, G.
(2003). Silibinin protects mice from T cell-dependent liver injury. J. Hepatol.
39, 333–340. doi: 10.1016/S0168-8278(03)00239-3
Shinohara, M. L., Jansson, M., Hwang, E. S., Werneck, M. B., Glimcher, L. H.,
and Cantor, H. (2005). T-bet-dependent expression of osteopontin contributes
to T cell polarization. Proc. Natl. Acad. Sci. U.S.A. 102, 17101–17106.
doi: 10.1073/pnas.0508666102
Siebler, J., Wirtz, S., Klein, S., Protschka, M., Blessing, M., Galle, P. R., et al.
(2003). A key pathogenic role for the STAT1/T-bet signaling pathway in T-cell-
mediated liver inflammation. Hepatology 38, 1573–1580. doi: 10.1016/j.hep.
2003.09.020
Stummvoll, G. H., DiPaolo, R. J., Huter, E. N., Davidson, T. S., Glass, D., Ward,
J. M., et al. (2008). Th1, Th2, and Th17 effector T cell-induced autoimmune
gastritis differs in pathological pattern and in susceptibility to suppression by
regulatory T cells. J. Immunol. 181, 1908–1916. doi: 10.4049/jimmunol.181.3.
1908
Frontiers in Pharmacology | www.frontiersin.org 8 March 2017 | Volume 8 | Article 140
fphar-08-00140 March 18, 2017 Time: 15:52 # 9
Sang et al. Liver Protection Effect of Sophocarpine
Tagawa, Y., Sekikawa, K., and Iwakura, Y. (1997). Suppression of concanavalin
A-induced hepatitis in IFN-gamma(-/-) mice, but not in TNF-alpha(-/-) mice:
role for IFN-gamma in activating apoptosis of hepatocytes. J. Immunol. 159,
1418–1428.
Tamaru, M., Nishioji, K., Kobayashi, Y., Watanabe, Y., Itoh, Y., Okanoue, T.,
et al. (2000). Liver-infiltrating T lymphocytes are attracted selectively by IFN-
inducible protein-10. Cytokine 12, 299–308. doi: 10.1006/cyto.1999.0560
Torisu, T., Nakaya, M., Watanabe, S., Hashimoto, M., Yoshida, H., Chinen, T., et al.
(2008). Suppressor of cytokine signaling 1 protects mice against concanavalin
A–induced hepatitis by inhibiting apoptosis. Hepatology 47, 1644–1654.
doi: 10.1002/hep.22214
Wang, H. X., Liu, M., Weng, S. Y., Li, J. J., Xie, C., He, H. L., et al. (2012). Immune
mechanisms of Concanavalin A model of autoimmune hepatitis. World J.
Gastroenterol. 18, 119–125. doi: 10.3748/wjg.v18.i2.119
Xu, Y., Feng, D., Wang, Y., Lin, S., and Xu, L. (2008). Sodium tanshinone IIA
sulfonate protects mice from ConA-induced hepatitis via inhibiting NF-kappaB
and IFN-gamma/STAT1 pathways. J. Clin. Immunol. 28, 512–519. doi: 10.1007/
s10875-008-9206-3
Yoshimura, A. (2009). Regulation of cytokine signaling by the SOCS and Spred
family proteins. Keio J. Med. 58, 73–83. doi: 10.2302/kjm.58.73
Yoshimura, A., Suzuki, M., Sakaguchi, R., Hanada, T., and Yasukawa, H. (2012).
SOCS, inflammation, and autoimmunity. Front. Immunol. 3:20. doi: 10.3389/
fimmu.2012.00020
Yuan, H., Ma, Q., Ye, L., and Piao, G. (2016). The traditional medicine and
modern medicine from natural products. Molecules 21:E559. doi: 10.3390/
molecules21050559
Zhang, J., Wang, W., and Duan, Z. (2007). Progress of research and application of
matrine-type alkaloids. Prog. Mod. Biomed. 7, 451–455.
Zheng, W., Wang, Q., Lu, X., Shi, Q., Zou, J., Tao, Y., et al. (2016). Protective effects
of Dracocephalum heterophyllum in ConA-induced acute hepatitis. Mediators
Inflamm. 2016:2684321. doi: 10.1155/2016/2684321
Zhu, J., Yamane, H., and Paul, W. E. (2010). Differentiation of effector CD4 T
cell populations (∗). Annu. Rev. Immunol. 28, 445–489. doi: 10.1146/annurev-
immunol-030409-101212
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Sang, Wang, Zhang, Liu, Shen, Guo, Zhang, Niu, Wang, Bai
and Xiao. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 9 March 2017 | Volume 8 | Article 140
